|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.84 / 8.16|
-- Evaluation of IPI-549 as a Monotherapy Continuing, with Combination Portion of Phase 1 Study Expected to Begin This Fall --
Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc.
Verastem, Inc. (NASDAQ:VSTM) and Infinity Pharmaceuticals, Inc.
Transaction Adds Complementary Late-Stage Product Candidate from a Clinically Validated Drug Class to Verastem's Pipeline
The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 408,920 share increase in total short interest for Infinity Pharmaceuticals Inc , to 2,067,803, an increase of 24.65% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Infinity Pharmaceuticals (INFI) said preliminary results from its IPI-549 drug trial showed that the cancer treatment can reverse tumor resistance to checkpoint inhibitors.
- PI3K-Gamma Identified as a Critical Molecular Switch that Controls Immune Suppression -
- Infinity to Explore Strategic Options for Duvelisib Program to Support Global Regulatory Filings for Duvelisib -
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a weak on high relative volume candidate
Analysts cut valuation estimates for Infinity Pharmaceuticals after a disappointing drug study.
Analysts cut valuation estimates after a disappointing drug study.
Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate
Levi & Korsinsky announces it has commenced an investigation of Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals (INFI) stock is plunging after the company announced a restructuring following disappointing drug-study results.
Stocks were falling slightly in premarket trading Tuesday as oil continued its six-day descent.
- Infinity and AbbVie in Discussions to Explore Possible Options for the Duvelisib Collaboration -
- Campaign Designed to Educate and Engage Community and Academic Oncologists on the Role of the Tumor Microenvironment in B-Cell Malignancies -
-- Preliminary Data from CONTEMPO, a Phase 1b/2 Combination Study Evaluating Duvelisib in Treatment-Naive Patients with Follicular Lymphoma, to Be Presented at EHA --